subscribeSubscribe
Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination
FDA
21 Nov 2023
Share Share
Bayer recalls one lot of cancer drug Vitrakvi due to contamination

Bayer recalls one lot of cancer drug Vitrakvi due to contamination
BUSINESSWIRE
18 Nov 2023
Share Share
Latest Vitrakvi Subgroup Analyses at ASCO 2023 Showcase Long-Term Efficacy

Latest Vitrakvi Subgroup Analyses at ASCO 2023 Showcase Long-Term Efficacy
BUSINESSWIRE
02 Jun 2023
Share Share
Tissue-agnostic drug development: FDA oncology center offers draft guidance

Tissue-agnostic drug development: FDA oncology center offers draft guidance
Zachary Brennan ENDPTS
18 Oct 2022
Share Share
Follow-Up Data on Bayer’s Larotrectinib Hints at Potentially Curative Impact

Follow-Up Data on Bayer’s Larotrectinib Hints at Potentially Curative Impact
Abbey Glasure BIOSPACE
06 Jul 2022
Share Share
Vitrakvi Support Consistently Meaningful Clinical Profile in TRK Fusion Cancer

Vitrakvi Support Consistently Meaningful Clinical Profile in TRK Fusion Cancer
BUSINESSWIRE
16 Sep 2021
Share Share
Precision oncology treatment Larotrectinib submitted for marketing in China

Precision oncology treatment Larotrectinib submitted for marketing in China
PRESS RELEASE
25 May 2021
Share Share
FDA approves Foundation Medicine`s diagnostic for Vitrakvi

FDA approves Foundation Medicine`s diagnostic for Vitrakvi
Ben Adams FIERCEBIOTECH
26 Oct 2020
Share Share
FDA Approves FoundationOne CDx for Larotrectinib in NTRK+ Tumors

FDA Approves FoundationOne CDx for Larotrectinib in NTRK+ Tumors
Gina Mauro PRESS RELEASE
23 Oct 2020
Share Share
Bayer’s Vitrakvi shows long-term efficacy in TRK fusion-positive cancers

Bayer’s Vitrakvi shows long-term efficacy in TRK fusion-positive cancers
Lucy Parsons PHARMATIMES
18 Sep 2020
Share Share